Brokerages expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to post ($0.65) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.68). Zynerba Pharmaceuticals reported earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year over year growth rate of 8.3%. The business is expected to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.63) per share for the current year, with EPS estimates ranging from ($2.96) to ($2.30). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.74) to ($2.18). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Monday, March 12th. The company reported ($0.60) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.60). During the same quarter in the prior year, the business posted ($0.71) EPS.
Shares of ZYNE stock opened at $8.85 on Friday. The firm has a market cap of $123.95, a PE ratio of -3.58 and a beta of 5.06. Zynerba Pharmaceuticals has a 52 week low of $5.42 and a 52 week high of $25.95.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were acquired at an average price of $12.99 per share, with a total value of $194,850.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.91% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of ZYNE. New York State Common Retirement Fund bought a new position in shares of Zynerba Pharmaceuticals in the second quarter worth approximately $207,000. Northern Trust Corp lifted its stake in shares of Zynerba Pharmaceuticals by 420.5% in the second quarter. Northern Trust Corp now owns 135,876 shares of the company’s stock worth $2,306,000 after buying an additional 109,770 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Zynerba Pharmaceuticals by 12.4% in the second quarter. Vanguard Group Inc. now owns 478,763 shares of the company’s stock worth $8,125,000 after buying an additional 52,952 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Zynerba Pharmaceuticals in the second quarter worth approximately $223,000. Finally, State Street Corp bought a new position in shares of Zynerba Pharmaceuticals in the second quarter worth approximately $2,698,000. Hedge funds and other institutional investors own 28.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “-$0.65 Earnings Per Share Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3294451/0-65-earnings-per-share-expected-for-zynerba-pharmaceuticals-inc-zyne-this-quarter.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.